Published in Oncologist on January 01, 2002
EGFR associated expression profiles vary with breast tumor subtype. BMC Genomics (2007) 3.35
Systemic treatment of colorectal cancer. Gastroenterology (2008) 2.62
Matuzumab binding to EGFR prevents the conformational rearrangement required for dimerization. Cancer Cell (2008) 2.21
Cellular responses to EGFR inhibitors and their relevance to cancer therapy. Cancer Lett (2007) 1.62
Tumor immune escape by the loss of homeostatic chemokine expression. Proc Natl Acad Sci U S A (2007) 1.58
Responses of cancer cells with wild-type or tyrosine kinase domain-mutated epidermal growth factor receptor (EGFR) to EGFR-targeted therapy are linked to downregulation of hypoxia-inducible factor-1alpha. Mol Cancer (2007) 1.27
Human CMV infection of endothelial cells induces an angiogenic response through viral binding to EGF receptor and beta1 and beta3 integrins. Proc Natl Acad Sci U S A (2008) 1.25
Alteration of the serum levels of the epidermal growth factor receptor and its ligands in patients with non-small cell lung cancer and head and neck carcinoma. Br J Cancer (2007) 1.25
Preclinical evaluation of a monoclonal antibody targeting the epidermal growth factor receptor as a radioimmunodiagnostic and radioimmunotherapeutic agent. Br J Pharmacol (2009) 1.21
Cetuximab and irinotecan as third-line therapy in advanced colorectal cancer patients: a single centre phase II trial. Br J Cancer (2006) 1.14
EGFR-targeting drugs in combination with cytotoxic agents: from bench to bedside, a contrasted reality. Br J Cancer (2008) 1.13
Emerging therapies in gastrointestinal cancers. World J Gastroenterol (2006) 1.11
Heregulin beta1 drives gefitinib-resistant growth and invasion in tamoxifen-resistant MCF-7 breast cancer cells. Breast Cancer Res (2007) 1.08
Molecular features and survival outcomes of the intrinsic subtypes within HER2-positive breast cancer. J Natl Cancer Inst (2014) 1.08
The tumor microenvironment: the making of a paradigm. Cancer Microenviron (2009) 1.06
Aptamers selected against the unglycosylated EGFRvIII ectodomain and delivered intracellularly reduce membrane-bound EGFRvIII and induce apoptosis. Biol Chem (2009) 1.05
Personalized colon cancer care in 2010. Semin Oncol (2011) 1.01
A review on angiogenesis and its assays. Iran J Basic Med Sci (2012) 1.00
A Phase I, open-label, dose-escalation study of continuous once-daily oral treatment with afatinib in patients with advanced solid tumors. Invest New Drugs (2012) 0.96
Gefitinib ('Iressa', ZD1839) and new epidermal growth factor receptor inhibitors. Br J Cancer (2004) 0.96
Toxicity and efficacy evaluation of multiple targeted polymalic acid conjugates for triple-negative breast cancer treatment. J Drug Target (2013) 0.95
Epidermal growth factor receptor status and persistent activation of Akt and p44/42 MAPK pathways correlate with the effect of cetuximab in head and neck and colon cancer cell lines. J Cancer Res Clin Oncol (2008) 0.95
Nanobiopolymer for direct targeting and inhibition of EGFR expression in triple negative breast cancer. PLoS One (2012) 0.95
Gallic acid reduces cell viability, proliferation, invasion and angiogenesis in human cervical cancer cells. Oncol Lett (2013) 0.93
Chemoradiotherapy for colorectal cancer. Gut (2005) 0.93
Hydrogel-based protein array for quantifying epidermal growth factor receptor activity in cell lysates. Anal Biochem (2009) 0.90
Breast cancer subtypes: response to radiotherapy and potential radiosensitisation. Br J Radiol (2013) 0.90
Nonlinear pharmacokinetics of therapeutic proteins resulting from receptor mediated endocytosis. J Pharmacokinet Pharmacodyn (2009) 0.89
A Phase I, open-label, dose escalation study of afatinib, in a 3-week-on/1-week-off schedule in patients with advanced solid tumors. Invest New Drugs (2012) 0.89
Selective inhibition of TNF-alpha-induced activation of mitogen-activated protein kinases and metastatic activities by gefitinib. Br J Cancer (2005) 0.88
Molecular genetics and targeted therapeutics in biliary tract carcinoma. World J Gastroenterol (2016) 0.86
Anti-angiogenic therapies for metastatic colorectal cancer: current and future perspectives. World J Gastroenterol (2013) 0.85
Current status of pharmacological treatment of colorectal cancer. World J Gastrointest Oncol (2014) 0.85
A novel approach in the treatment of neuroendocrine gastrointestinal tumours. Targeting the epidermal growth factor receptor by gefitinib (ZD1839). Br J Cancer (2003) 0.85
Combining erlotinib and cetuximab is associated with activity in patients with non-small cell lung cancer (including squamous cell carcinomas) and wild-type EGFR or resistant mutations. Mol Cancer Ther (2013) 0.85
Displayed correlation between gene expression profiles and submicroscopic alterations in response to cetuximab, gefitinib and EGF in human colon cancer cell lines. BMC Cancer (2008) 0.85
Epidermal growth factor receptor expression in esophageal adenocarcinoma: relationship with tumor stage and survival after esophagectomy. Gastroenterol Res Pract (2012) 0.84
Photoimmunotherapy and irradiance modulation reduce chemotherapy cycles and toxicity in a murine model for ovarian carcinomatosis: perspective and results. Isr J Chem (2012) 0.83
Combined effect of gefitinib ('Iressa', ZD1839) and targeted radiotherapy with 211At-EGF. Eur J Nucl Med Mol Imaging (2003) 0.83
Quantification of Epidermal Growth Factor Receptor Expression Level and Binding Kinetics on Cell Surfaces by Surface Plasmon Resonance Imaging. Anal Chem (2015) 0.82
Signaling pathways involved in the inhibition of epidermal growth factor receptor by erlotinib in hepatocellular cancer. World J Gastroenterol (2006) 0.82
Prolidase directly binds and activates epidermal growth factor receptor and stimulates downstream signaling. J Biol Chem (2012) 0.82
The EGF 61A/G polymorphism - a predictive marker for recurrence of liver metastases from colorectal cancer. Wien Klin Wochenschr (2009) 0.82
Tyrosine kinase receptor EGFR regulates the switch in cancer cells between cell survival and cell death induced by autophagy in hypoxia. Autophagy (2016) 0.81
EGFR(s) in aging and carcinogenesis of the gastrointestinal tract. Curr Protein Pept Sci (2010) 0.81
Pretreatment levels of the serum biomarkers CEA, CYFRA 21-1, SCC and the soluble EGFR and its ligands EGF, TGF-alpha, HB-EGF in the prediction of outcome in erlotinib treated non-small-cell lung cancer patients. Springerplus (2015) 0.81
Engineering of PDMS surfaces for use in microsystems for capture and isolation of complex and biomedically important proteins: epidermal growth factor receptor as a model system. Lab Chip (2008) 0.81
Treatment of vestibular schwannoma cells with ErbB inhibitors. Otol Neurotol (2012) 0.81
GEM-loaded magnetic albumin nanospheres modified with cetuximab for simultaneous targeting, magnetic resonance imaging, and double-targeted thermochemotherapy of pancreatic cancer cells. Int J Nanomedicine (2015) 0.80
Multi-Scale Genomic, Transcriptomic and Proteomic Analysis of Colorectal Cancer Cell Lines to Identify Novel Biomarkers. PLoS One (2015) 0.80
FTS is responsible for radiation-induced nuclear phosphorylation of EGFR and repair of DNA damage in cervical cancer cells. J Cancer Res Clin Oncol (2014) 0.79
Chemo-immunotherapy of colorectal carcinoma: preclinical rationale and clinical experience. Invest New Drugs (2006) 0.78
Current status and perspective of angiogenesis and antivascular therapeutic strategy: non-small cell lung cancer. Int J Clin Oncol (2006) 0.78
TAp73 is one of the genes responsible for the lack of response to chemotherapy depending on B-Raf mutational status. J Transl Med (2010) 0.77
Serum calprotectin, CD26 and EGF to establish a panel for the diagnosis of lung cancer. PLoS One (2015) 0.77
Therapeutic options for intrahepatic cholangiocarcinoma. Hepatobiliary Surg Nutr (2017) 0.75
A phase I study of nimotuzumab plus docetaxel in chemotherapy-refractory/resistant patients with advanced non-small-cell lung cancer. Chin J Cancer Res (2016) 0.75
Correlation of EGFR or KRAS mutation status with 18F-FDG uptake on PET-CT scan in lung adenocarcinoma. PLoS One (2017) 0.75
Cetuximab intensifies the ADCC activity of adoptive NK cells in a nude mouse colorectal cancer xenograft model. Oncol Lett (2016) 0.75
Treatment of Cultured Sebocytes with an EGFR Inhibitor Does Not Lead to Significant Upregulation of Inflammatory Biomarkers. Ann Dermatol (2011) 0.75
The 'Iressa' Clinical Experience Meeting. June 2003, Madrid, Spain. Proceedings and abstracts. Br J Cancer (2003) 0.75
Epidermal growth factor receptor and metastatic colorectal cancer: insights into target therapies. World J Gastroenterol (2013) 0.75
Nimotuzumab, a novel monoclonal antibody to the epidermal growth factor receptor, in the treatment of non-small cell lung cancer. Lung Cancer (Auckl) (2011) 0.75
Targeting Metabolic Remodeling in Triple Negative Breast Cancer in a Murine Model. J Cancer (2017) 0.75
Characterization of surfaces presenting covalently immobilized oligopeptides using near-edge X-ray absorption fine structure spectroscopy. Langmuir (2010) 0.75
Gefitinib enhances the effects of combined radiotherapy and 5-fluorouracil in a colorectal cancer cell line. Int J Colorectal Dis (2013) 0.75
[Cutaneous lesions due to inhibition of epidermal growth factor receptor]. Pathologe (2006) 0.75